Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene regulatory network analysis on snRNAseq revealed key regulators for hepatocellular carcinoma progression

ABSTRACT: Many clinical researchers have developed targeted therapy and immunotherapy for the case of advanced stage of hepatocellular carcinoma (HCC). However, the molecular mechanisms of HCC development still need to be investigated to improve the response rate of those therapies. Here, we generated single nucleus RNA sequencing (snRNAseq) data from biopsy samples of six patients with Barcelona Clinic Liver Cancer (BCLC) advanced C stage. We first found that the gene expression heterogeneity in hepatocytes was mainly dissected by vascular invasion. To identify the key regulators of malignant progression of hepatocytes, we applied TENET, a gene regulatory network (GRN) inference tool based on pseudotime-ordered single cell expression. TENET predicts that MLXIPL and CUX1 are the top two regulators and regulate each other. This prediction was comprehensively validated by overexpression and knockdown of CUX1 in two HCC cell lines. This study suggested that GRN analysis with single cell transcriptomics provides new therapeutic targets for HCC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE278324 | GEO | 2025/09/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression of tsRNAs in early stage hepatocellular carcinoma

Project description:This work utilized Arraystar Human tRF&tiRNA sequencing technology to conduct a thorough investigation of tsRNA expression profiles. The objective was to identify and assess the potential of tsRNAs as early diagnostic indicators for HCC. Effectively identifying a specific set of tsRNAs that displayed distinct expression patterns in Barcelona Clinic Liver Cancer (BCLC) 0/A stage HCC tissues in comparison to normal liver tissues.

2025-01-01 | GSE282472 | GEO

Proteome Landscape of Early Stage Hepatocellular Carcinoma Identifies Proteomic Subtypes and New Therapeutic Targets - Phosphorylation data

Project description:Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancers, the second leading cause of cancer mortality worldwide. Although HCC surgical treatment may be curative in the early stages, its five-year overall survival is only 50-70%. Advances in proteomic technologies have expanded the breadth and depth of cancer proteome characterization. Here, we present the largest characterization effort on proteomic profiling of 222 tumor and paired non-tumor tissues in clinically early HCC (Barcelona Clinic Liver Cancer (BCLC) stage 0 and A). Quantitative proteomic data identified three more-refined subtypes in the early- stage cohort of HCC (termed S-I, S-II and S-III) with different clinical outcomes. S-I retained hepatic detoxification and metabolic functions with the best prognosis, S-II increased molecular expression related to proliferation, and S-III showed distinct enrichment of tumor metastasis and immune response pathways and the poorest prognosis. The subtype specific signatures targeted by known FDA approved drugs or inhibitors under clinical investigations for HCC provide a novel resource for HCC therapeutic targets. A new mechanism of disrupted cholesterol homeostasis with aberrant accumulation of cholesteryl esters was also highlighted in S-III. Thus, this study represents the first proteomic stratification of early-stage HCC, providing insights into tumor biology and personalized targeted therapy.

2019-03-01 | PXD008373 | Pride

Proteome Landscape of Early Stage Hepatocellular Carcinoma Identifies Proteomic Subtypes and New Therapeutic Targets

2019-05-29 | PXD006512 | Pride

Single-cell analysis reveals the landscape of tumor heterogeneity and identifies MLXIPL as a potential biomarker in tumor evolution trajectory of hepatocellular carcinoma

Project description:Hepatocellular carcinoma (HCC) is a globally prevailing cancer with a low five-year survival rate. Little is known about its intricate gene expression profile and tumor evolutionary traits. Single-cell RNA sequencing (scRNA-seq) is an indispensable tool to explore the genetic characteristics at the single-cell level. In this study, we profiled gene expression of single cells from human HCC tumor and para-tumor tissues using Smart-seq 2 sequencing method. Based on DEGs, we identified heterogeneous subclones in HCC tissues, including 4 HCC and 2 hepatocyte subclones. Then, we carried out hub-gene co-network and functional annotations analysis to further explain tumor heterogeneity. Next, we conducted the evolution trajectory by pseudo-time analysis and its regulated transcriptional factors (TF) gene network. In the following research, we found that MLXIPL, as a TF, was commonly upregulated in HCC tissues and cells at both the mRNA and protein levels, promoting cell proliferation and inhibiting its apoptosis. Mechanistically, MLXIPL activation is crucial for accelerating HCC cell glycolysis. Taken together, our work identified the heterogeneity of HCC cell subclones, and MLXIPL might be a promising therapeutic target of HCC.

2021-01-27 | GSE154906 | GEO

snRNAseq of bCat-Kras tumors in normal and NASH diet

Project description:Current models of hepatocellular tumorigenesis propose that the chronic injury and inflammation in NASH are mutagenic and growth promoting which can eventually lead to HCC. However, contrary to this model, here we show that NASH suppresses the early development of liver cancers in mice. We found that NASH did not hinder the malignant reprogramming of oncogene expressing hepatocytes but suppressed their clonal expansion and led to their elimination. This elimination was not caused by a direct effect of NASH on malignant cells but due to the stimulation of cell competition in tumor-surrounding hepatocytes. Mechanistically, NASH activated the Hippo pathway effectors Yap and Taz in hepatocytes, which elevated their cellular fitness. Thus, deletion of Yap/Taz in tumor-surrounding hepatocytes abolished the elimination of tumor cells by NASH, while experimental hyperactivation of Yap in malignant cells protected them from NASH-induced elimination

2025-09-01 | GSE241856 | GEO

Genome-wide Mapping of 5-Hydroxymethylcytosines in Circulating Cell-free DNA as a Non-invasive Approach for Early Detection of Hepatocellular Carcinoma

Project description:Background: The lack of highly sensitive and specific diagnostic biomarkers is a major contributor to the poor outcomes of patients with hepatocellular carcinoma (HCC). We sought to develop a non-invasive diagnostic approach using circulating cell-free DNA (cfDNA) for the early detection of HCC. Methods: Applying the 5hmC-Seal technique, we obtained genome-wide 5-hydroxymethylcytosines (5hmC) in cfDNA samples from 2,554 Chinese subjects: 1,204 HCC patients, 392 patients with chronic hepatitis B virus infection (CHB) or liver cirrhosis (LC), and 958 healthy individuals and patients with benign liver lesions. A diagnostic model for early HCC was developed through case-control analyses using the elastic net regularization for feature selection. Results: The 5hmC-Seal data from HCC patients showed a genome-wide distribution enriched with liver-derived enhancer marks. We developed a 32-gene diagnostic model that accurately distinguished early HCC (stage 0/A) based on the Barcelona Clinic Liver Cancer (BCLC) staging system from non-HCC (validation set: AUC = 88.4%; 95% CI, 85.8-91.1%), showing superior performance over α-fetoprotein (AFP). Besides detecting patients with early stage or small tumors (e.g., ≤ 2.0 cm) from non-HCC, the 5hmC model showed high capacity for distinguishing early HCC from high risk subjects with CHB or LC history (validation set: AUC = 84.6%; 95% CI, 80.6-88.7%), also significantly outperforming AFP. Furthermore, the 5hmC diagnostic model appeared to be independent from potential confounders (e.g., smoking/alcohol intake history). Conclusions: We have developed and validated a non-invasive approach with clinical application potential for the early detection of HCC that are still surgically resectable in high risk individuals.

2019-08-07 | GSE112679 | GEO

TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway [RNA-Seq]

Project description:Hepatocellular carcinoma (HCC) is a formidable malignancy with limited effective therapeutic avenues. This study was designed to investigate the role of transglutaminase 2 (TGM2) in promoting HCC progression and assess its potential as a target for therapeutic intervention in HCC treatment.TMG2 expression was positively related to a higher AFP level, poor differentiation, and a later BCLC stage. Tgm2 deficiency or H3Q5ser inhibition notably restrained HCC progression. Mechanism research revealed that TGM2-mediated H3Q5ser modifications promote HCC progression via MYC pathway signaling. Furthermore, transcriptional intermediary factor 1 beta (TIF1-β/TRIM28) mediated the recruitment of TGM2 by MYC to facilitate H3Q5ser modifications on MYC targets. Finally, targeting the TGM2 transglutaminase activity significantly suppressed HCC progression in preclinical models.

2024-12-16 | GSE283279 | GEO

TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway [Cut & Tag]

2024-12-16 | GSE283278 | GEO

Plasma proteomic signature for predicting survival in advanced HCC

Project description:Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality globally, with over 70% of patients diagnosed at intermediate or advanced stages (BCLC B/C) where curative treatments are no longer feasible. Conventional prognostic tools fail to capture this complexity, highlighting the urgent need for precise predictive models integrating molecular and clinical data. Methods: We conducted a retrospective cohort study of 242 patients with advanced HCC (BCLC B-D) treated with first-line systemic therapy (110 deaths and 152 survivors) at admitted to the Beijing Ditan Hospital of Capital Medical University between October 2021 and December 2023. Plasma proteomic analysis was obtained using DB4000 Deep Blood DIA Proteome combined with Data Independent Acquisition (DIA) and Astral Mass Spectrometry platform. Principal component analysis and differential protein abundance analysis are used to evaluate proteomic changes between two groups of patients. ELISA quantitative verification of protein biomarker phenological selection, single-cell transcriptome sequencing analysis of the expression of target protein in HCC tissue and its relationship with prognosis.

2025-11-23 | PXD071115 |

A human liver cell-based system modeling a clinical prognostic liver signature combined with single-cell RNA-Seq for discovery of liver disease therapeutics

Project description:Abstract: Chronic liver disease and hepatocellular carcinoma (HCC) are life-threatening with limited treatment options. The lack of clinically relevant/tractable experimental models hampers therapeutic discovery. We developed a simple and robust human liver cell-based system modeling a clinical prognostic liver signature (PLS) predicting long-term liver disease progression toward HCC. Using the PLS as a readout, followed by validation in NASH-HCC animal models and patient-derived tumorspheroids, we identified nizatidine, a histamine receptor H2 (HRH2) blocker, for treatment of advanced liver disease and HCC chemoprevention. Perturbation studies combined with scRNA-Seq analyses of patient liver tissues uncovered HRH2+, CLEC5Ahigh, MARCOlow liver macrophages and hepatocytes as nizatidine targets. The PLS model combined with scRNA-Seq of patient tissues enables discovery of urgently needed targets and therapeutics for treatment of advanced liver disease and cancer prevention.

2021-07-01 | GSE173671 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data